Welcome to our dedicated page for Ovid Therapeutics news (Ticker: OVID), a resource for investors and traders seeking the latest updates and insights on Ovid Therapeutics stock.
Ovid Therapeutics Inc. reports developments as a biopharmaceutical company developing targeted small-molecule medicines for brain disorders and symptoms linked to excess neural excitability. Recurring news centers on its KCC2 direct-activator portfolio, including OV350, OV4071 and next-generation candidates, as well as OV329, a next-generation GABA-aminotransferase inhibitor being developed for treatment-resistant seizures and related rare epileptic disorders.
Company updates also cover clinical and translational data, regulatory clearances for early-stage studies, R&D events, financial results, private-placement and warrant-related capital actions, investor conference participation, and leadership or governance changes tied to the advancement of its CNS pipeline.
Ovid Therapeutics (NASDAQ: OVID) announced a private placement (PIPE) expected to raise up to $175 million in gross proceeds, including initial gross proceeds of approximately $81 million, before fees and expenses. The PIPE is expected to close on or about October 6, 2025, subject to customary conditions and stockholder approvals.
The financing sells 57,722 shares of Series B preferred, Series A warrants to purchase 38,481,325 common shares and Series B warrants to purchase 28,861,000 common shares. If all preferred conversions and warrants are exercised for cash, Ovid would receive aggregate additional proceeds and issue a total of 125,064,325 common shares. The Company expects existing cash plus initial PIPE proceeds to fund operations into 2028.
Ovid (NASDAQ: OVID) announced positive topline Phase 1 results for OV329 on Oct 3, 2025. In 68 healthy volunteers (51 active; 17 placebo) OV329 5 mg produced robust biomarker evidence of GABA-AT inhibition: LICI inhibition +53% (p=0.0001) on APB and CSP prolongation +12.9 ms (FDI; p=0.00012). MRS showed mean GABA +7.13% in the medial parietal lobe at 5 mg (n=14). Safety was favorable: all treatment-related AEs were mild/transient and no ophthalmic/retinal changes observed through Day 30. Ovid plans a randomized Phase 2a in drug-resistant focal onset seizures in Q2 2026 and will complete enabling work for oral KCC2 activator OV4071 in early 2026.
Ovid Therapeutics (NASDAQ:OVID) reported Q2 2025 financial results and provided key pipeline updates. The company ended Q2 with $38.3 million in cash, expected to fund operations into early 2H 2026. Key highlights include the anticipated Q3 2025 topline readout for OV329 Phase 1 trial, a next-generation GABA-AT inhibitor for treatment-resistant seizures, and a $7.0 million royalty monetization deal with Immedica Pharma AB for ganaxolone rights.
The company is advancing its KCC2 activator portfolio, with OV350's safety data expected in Q4 2025 and OV4071, the first oral KCC2 activator, progressing toward first-in-human studies in Q2 2026. Q2 financial results showed revenues of $6.3 million and a net loss of $4.7 million ($0.06 per share), with reduced operating expenses of $11.3 million compared to $20.7 million in Q2 2024.
Ovid Therapeutics (NASDAQ:OVID), a biopharmaceutical company focused on developing small molecule medicines for brain conditions, announced its participation in the upcoming BTIG Virtual Biotechnology Conference. The conference is scheduled for July 29-30, 2025.
Ovid Therapeutics (NASDAQ:OVID) has entered into a definitive agreement with Immedica Pharma AB to sell its future ganaxolone royalty rights outside China for $7 million in cash. The deal includes the transfer of royalty rights from Ovid's 2022 agreement with Marinus Pharmaceuticals for ganaxolone use in CDKL5 deficiency disorder (CDD). Immedica will also acquire or license Ovid's global ganaxolone intellectual property portfolio and assume related costs.
The transaction provides non-dilutive funding to extend Ovid's operational runway. For reference, Ovid recorded $566,000 in ganaxolone royalty revenues in 2024. The deal has no impact on Ovid's current pipeline as the company has not been pursuing ganaxolone development.
Ovid Therapeutics (NASDAQ: OVID), a biopharmaceutical company focused on developing medicines for brain conditions, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.
The company's President and Chief Operating Officer, Meg Alexander, will deliver a presentation on Monday, April 7, 2025, at 8:45 AM ET.
Investors and interested parties can access the live webcast through the Events & Presentations section at investors.ovidrx.com. A replay will remain available on the company's website for approximately 30 days after the presentation.
Ovid Therapeutics (NASDAQ: OVID) reported its Q4 and full-year 2024 financial results, highlighting key pipeline developments and organizational updates. The company ended 2024 with $53.1 million in cash and equivalents, expected to fund operations into H2 2026.
Key developments include: appointment of Dr. Stelios Papadopolous to the Board of Directors; anticipated topline results from OV329's Phase 1 study in Q3 2025; and initiation of first-in-human study for OV350 in Q1 2025. The company reported full-year 2024 revenues of $566,000 and a net loss of $26.4 million ($0.37 per share).
Pipeline updates include:
- OV329: Phase 1 study progressing with no serious adverse events reported
- OV350: First KCC2 direct activator initiated human trials
- OV4071: First oral KCC2 activator targeting human studies in Q2 2026
- OV888/GV101: Phase 2 proof-of-concept study paused for strategic evaluation
Ovid Therapeutics (Nasdaq: OVID) has appointed Dr. Stelios Papadopoulos to its Board of Directors. Dr. Papadopoulos, a renowned scientist, investor, and entrepreneur with over four decades of biotechnology experience, will serve on the company's Audit and Compensation Committees.
The appointment comes at a strategic time as Ovid advances its pipeline, including novel KCC2 direct activators and OV329 epilepsy program, focusing on developing small-molecule medicines for brain conditions with significant unmet need.
Dr. Papadopoulos brings extensive experience from his roles at Cowen & Co., PaineWebber, and academic positions. He currently serves as Chairman of Exelixis and Regulus Therapeutics, and was previously Chairman of Biogen. He holds an MS in physics, PhD in biophysics, and MBA in finance from New York University.